Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

$108.88 -4.32 (-3.81%)

As of 10:33 AM Eastern

Jazz Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
1

Buy
13

Based on 14 Wall Street analysts who have issued ratings for Jazz Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a hold rating, and 13 have given a buy rating for JAZZ.

Consensus Price Target

$181.64
66.82% Upside

According to the 14 analysts' twelve-month price targets for Jazz Pharmaceuticals, the average price target is $181.64. The highest price target for JAZZ is $230.00, while the lowest price target for JAZZ is $147.00. The average price target represents a forecasted upside of 66.82% from the current price of $108.89.

Get the Latest News and Ratings for JAZZ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Jazz Pharmaceuticals and its competitors.

JAZZ Analyst Ratings Over Time

Type	Current Forecast 8/6/24 to 8/6/25	1 Month Ago 7/7/24 to 7/7/25	3 Months Ago 5/8/24 to 5/8/25	1 Year Ago 8/7/23 to 8/6/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$181.64	$184.00	$182.79	$175.20
Forecasted Upside	66.82% Upside	71.00% Upside	85.95% Upside	57.31% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

JAZZ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JAZZ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Jazz Pharmaceuticals Stock vs. The Competition

Type	Jazz Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.93	2.81	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	60.46% Upside	11,055.06% Upside	13.60% Upside
News Sentiment Rating	Positive News See Recent JAZZ News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/22/2025	Morgan Stanley 3 of 5 stars	Jeffrey Hung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$166.00 ➝ $165.00	+43.83%
7/15/2025	Deutsche Bank Aktiengesellschaft 3 of 5 stars	David Hoang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$152.00	+36.40%
6/11/2025	Needham & Company LLC 2 of 5 stars	Ami Fadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00	+78.76%
5/7/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$182.00 ➝ $172.00	+68.27%
5/7/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joel Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$167.00 ➝ $155.00	+51.64%
5/7/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Amsellem Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$176.00 ➝ $147.00	+40.21%
3/10/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Oren Livnat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$200.00 ➝ $217.00	+56.33%
3/7/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ashwani Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$145.00 ➝ $179.00	+31.18%
3/6/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gregory Fraser Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$220.00 ➝ $230.00	+68.12%
2/27/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Balaji Prasad Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$190.00 ➝ $200.00	+38.73%
Get the Latest News and Ratings for JAZZ and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
2/26/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Charles Duncan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$140.00 ➝ $150.00	+3.74%
2/26/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$200.00 ➝ $209.00	+44.05%
2/13/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$130.00 ➝ $170.00	+25.52%
11/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$200.00 ➝ $195.00	+62.80%
6/5/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$169.00	+61.75%
3/15/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$225.00 ➝ $230.00	+87.04%
9/28/2023	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
8/10/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$204.00 ➝ $217.00	+60.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:34 AM ET.

JAZZ Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Jazz Pharmaceuticals is $181.64, with a high forecast of $230.00 and a low forecast of $147.00.
: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There is currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JAZZ shares.
: According to analysts, Jazz Pharmaceuticals's stock has a predicted upside of 66.82% based on their 12-month stock forecasts.
: Jazz Pharmaceuticals has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Morgan Stanley, and Needham & Company LLC in the past 90 days.
: Analysts like Jazz Pharmaceuticals more than other "medical" companies. The consensus rating score for Jazz Pharmaceuticals is 2.93 while the average consensus rating score for "medical" companies is 2.81. Learn more on how JAZZ compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:JAZZ) was last updated on 8/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target